Stocks Health care RNTX
NASDAQ · Health careRein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $49.8M. At June 30, 2026 it held $8.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Rein Therapeutics, Inc. does
Rein Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$49.9M | -$1.96 | n/a |
| 2024 | $0 | -$62.9M | -$3.51 | n/a |
| 2023 | $0 | -$15.7M | -$3.42 | n/a |
| 2022 | $0 | -$27.3M | -$6.02 | n/a |
| 2021 | $0 | -$26.2M | -$5.89 | -$23.9M |
| 2020 | $0 | -$27.3M | -$12.39 | -$20.5M |
Latest SEC filings
What Rein Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 4, 2026
- August 27, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 21, 2026
- July 14, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
- June 8, 2026Additional proxy material DEFA14A
Questions about RNTX
What does Rein Therapeutics, Inc. do?
Rein Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNTX.
Is Rein Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.8M.
How much revenue does Rein Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Rein Therapeutics, Inc. reported revenue of $0.
When did Rein Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 4, 2026.
Similar companies
Follow RNTX
Get an email when Rein Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RNTX: get an email when it filesWhere the numbers come from
Financial figures are the values Rein Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.